[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594271":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":64,"collaborators":12,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":12,"enrollmentInfo":75,"targetDuration":12,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":40,"whyStopped":12,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Unity Health Toronto","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care Group","NO_INTERVENTION","This treatment arm comprises a strategy of usual care for type 2 diabetes mellitus",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Semaglutide","EXPERIMENTAL","Individuals randomized to this arm will take semaglutide once weekly.",[18],"Drug: Semaglutide Pen",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Semaglutide Pen","Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.",[14],[26],{"name":27,"affiliation":5,"role":28},"Dr. Ron Wald, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"Ron Wald, MD","CONTACT","(416) 867-3703","ron.wald@unityhealth.to",{"name":36,"role":32,"phone":12,"phoneExt":12,"email":37},"Kevin Yau, MD","Kevin.Yau@uhn.ca",[39,55],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Toronto","Ontario","M5B1W8","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-79.39864,43.70643,{"lat":50,"lon":49},[53,54],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},{"name":36,"role":32,"phone":12,"phoneExt":12,"email":37},{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},{"type":47,"coordinates":57},[49,50],{"lat":50,"lon":49},[60],{"name":61,"role":32,"phone":62,"phoneExt":12,"email":63},"Ivana Prce","416 867 7460 x 48109","ivana.prce@unityhealth.to",{"type":65,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100594271","phase-4-glucagon-like-peptide-1-receptor-agonists-in-patients-receiving-maintenance-dialysis-100594271",false,"NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA","ALL","18 Years",{"count":76,"type":77},100,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[83,84,85,86],"Kidney Disease, Chronic","Diabetes","Dialysis","End Stage Kidney Disease (ESRD)",[85,88,89,90,91,92],"Type 2 diabetes","semaglutide","end stage kidney disease","GLP1","GLP1RA","2026-06-22",{"date":95,"type":96},"2026-06-26","ACTUAL",{"date":98,"type":96},"2025-11-27",{"date":100,"type":77},"2027-09",{"name":5,"class":6},2]